{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:38Z","timestamp":1793745338299,"version":"4.6.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,23]],"date-time":"2027-02-23T00:00:00Z","timestamp":1803340800000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA266759"],"award-info":[{"award-number":["R01CA266759"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.actbio.2025.12.049","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:08:25Z","timestamp":1766794105000},"page":"637-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Dual Inhibition of KRAS G12D and PI3K\/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2214-4147","authenticated-orcid":false,"given":"Yashwardhan","family":"Ghanwatkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohan","family":"Mahto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaykumar","family":"Chittipolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram I.","family":"Mahato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.actbio.2025.12.049_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26157055","article-title":"Advances in the management of pancreatic cancer: current strategies and emerging therapies","volume":"26","author":"Peshin","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.actbio.2025.12.049_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112588","article-title":"Systemic therapy of metastatic pancreatic adenocarcinoma: current status, challenges, and opportunities","volume":"14","author":"Chakrabarti","year":"2022","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ. Precis. Oncol."},{"issue":"4","key":"10.1016\/j.actbio.2025.12.049_bib0004","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/gad.275776.115","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"30","author":"Ying","year":"2016","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.actbio.2025.12.049_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13072103","article-title":"The clinical implications of KRAS mutations and variant allele frequencies in pancreatic ductal adenocarcinoma","volume":"13","author":"Nusrat","year":"2024","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.actbio.2025.12.049_bib0006","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/PPO.0b013e31827ab4c4","article-title":"Genetically engineered mouse models of pancreatic cancer","volume":"18","author":"Westphalen","year":"2012","journal-title":"Cancer J."},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0007","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.actbio.2025.12.049_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102186","article-title":"Oncogenic KRAS G12C: kinetic and redox characterization of covalent inhibition","volume":"298","author":"Huynh","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.actbio.2025.12.049_bib0009","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s10555-020-09914-6","article-title":"Structure-based inhibitor design of mutant RAS proteins-a paradigm shift","volume":"39","author":"Ny\u00edri","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"10.1016\/j.actbio.2025.12.049_bib0010","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.actbio.2025.12.049_bib0011","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.actbio.2025.12.049_bib0012","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.actbio.2025.12.049_bib0013","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1021\/acsomega.3c00329","article-title":"Discovery of prodrug of MRTX1133 as an oral therapy for cancers with KRASG12D mutation","volume":"8","author":"Ji","year":"2023","journal-title":"ACS. Omega"},{"issue":"11","key":"10.1016\/j.actbio.2025.12.049_bib0014","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.actbio.2025.12.049_bib0015","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","article-title":"Dual inhibition of KRASG12D and Pan-ERBB is synergistic in pancreatic ductal adenocarcinoma","volume":"83","author":"Gulay","year":"2023","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.actbio.2025.12.049_bib0016","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.actbio.2025.12.049_bib0017","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/17425247.2018.1517746","article-title":"Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: advances and challenges","volume":"15","author":"Luther","year":"2018","journal-title":"Expert. Opin. Drug Deliv."},{"issue":"7_Supplement","key":"10.1016\/j.actbio.2025.12.049_bib0018","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-526","article-title":"RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D (ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers","volume":"83","author":"Jiang","year":"2023","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.actbio.2025.12.049_bib0019","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.3390\/cancers13215481","article-title":"Oncogenic KRAS-induced feedback inflammatory signaling in pancreatic cancer: an overview and new therapeutic opportunities","volume":"13","author":"Bansod","year":"2021","journal-title":"Cancers. (Basel)"},{"issue":"11","key":"10.1016\/j.actbio.2025.12.049_bib0020","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.actbio.2025.12.049_bib0021","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013502","article-title":"Pancreatic cancer intrinsic PI3K\u03b1 activity accelerates metastasis and rewires macrophage component","volume":"13","author":"Thibault","year":"2021","journal-title":"EMBo Mol. Med."},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0022","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"issue":"18","key":"10.1016\/j.actbio.2025.12.049_bib0023","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1073\/pnas.0802785105","article-title":"Activation of PI3K\/akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1","volume":"105","author":"Zhu","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.actbio.2025.12.049_bib0024","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-24-0831","article-title":"Combination therapy of avutometinib and MRTX1133 synergistically suppresses cell growth by inducing apoptosis in KRASG12D-mutated pancreatic cancer","author":"Toyokuni","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.actbio.2025.12.049_bib0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2022.12.055","article-title":"Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma","volume":"354","author":"Sethi","year":"2023","journal-title":"J. Control Release"},{"issue":"7","key":"10.1016\/j.actbio.2025.12.049_bib0026","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/17425247.2020.1767582","article-title":"Self-assembled block polymer aggregates in selective solution: controllable morphology transitions and their applications in drug delivery","volume":"17","author":"Jiao","year":"2020","journal-title":"Expert. Opin. Drug Deliv."},{"issue":"7","key":"10.1016\/j.actbio.2025.12.049_bib0027","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/14728222.2017.1323880","article-title":"MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma","volume":"21","author":"Gautam","year":"2017","journal-title":"Expert. Opin. Ther. Targets."},{"key":"10.1016\/j.actbio.2025.12.049_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2017.05.007","article-title":"Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205","volume":"402","author":"Chaudhary","year":"2017","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.actbio.2025.12.049_bib0029","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1021\/mp500847s","article-title":"Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer","volume":"12","author":"Kumar","year":"2015","journal-title":"Mol. Pharm."},{"issue":"25","key":"10.1016\/j.actbio.2025.12.049_bib0030","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.biomaterials.2014.04.053","article-title":"Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer","volume":"35","author":"Mittal","year":"2014","journal-title":"Biomaterials"},{"issue":"23","key":"10.1016\/j.actbio.2025.12.049_bib0031","doi-asserted-by":"crossref","first-page":"29686","DOI":"10.1021\/acsami.4c02626","article-title":"Gemcitabine\u2013Lipid conjugate and ONC201 combination therapy effectively treats orthotopic pancreatic tumor-bearing mice","volume":"16","author":"Shrestha","year":"2024","journal-title":"ACS. Appl. Mater. Interfaces."},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0032","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41420-024-01920-9","article-title":"Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model","volume":"10","author":"Kumar","year":"2024","journal-title":"Cell Death. Discov."},{"issue":"10","key":"10.1016\/j.actbio.2025.12.049_bib0033","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.102836","article-title":"An optimized protocol for isolation of murine pancreatic single cells with high yield and purity","volume":"5","author":"Wu","year":"2024","journal-title":"STAR. Protoc."},{"key":"10.1016\/j.actbio.2025.12.049_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1156769","article-title":"Characterization of 3D heterocellular spheroids of pancreatic ductal adenocarcinoma for the study of cell interactions in the tumor immune microenvironment","volume":"13","author":"Giustarini","year":"2023","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.actbio.2025.12.049_bib0036","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0037","doi-asserted-by":"crossref","first-page":"9803","DOI":"10.1038\/s41598-022-13764-3","article-title":"Role of CD47 in tumor immunity: a potential target for combination therapy","volume":"12","author":"Huang","year":"2022","journal-title":"Sci. Rep."},{"issue":"6282","key":"10.1016\/j.actbio.2025.12.049_bib0038","first-page":"227","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science (1979)"},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0039","doi-asserted-by":"crossref","first-page":"9657","DOI":"10.1038\/s41598-023-33915-4","article-title":"CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis","volume":"13","author":"Liu","year":"2023","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.actbio.2025.12.049_bib0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.mpa.0000160282.64451.f1","article-title":"Bcl-XL protein levels determine apoptotic index in pancreatic carcinoma","volume":"30","author":"Sharma","year":"2005","journal-title":"Pancreas."},{"issue":"11","key":"10.1016\/j.actbio.2025.12.049_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9110157","article-title":"Pancreatic cancer chemoresistance to Gemcitabine","volume":"9","author":"Amrutkar","year":"2017","journal-title":"Cancers. (Basel)"},{"issue":"9","key":"10.1016\/j.actbio.2025.12.049_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23095042","article-title":"Syntheses of polypeptides and their biomedical application for anti-tumor drug delivery","volume":"23","author":"Feng","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"46","key":"10.1016\/j.actbio.2025.12.049_bib0043","doi-asserted-by":"crossref","first-page":"eabd6764","DOI":"10.1126\/sciadv.abd6764","article-title":"Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy","volume":"6","author":"Xin","year":"2020","journal-title":"Sci. Adv."},{"issue":"10","key":"10.1016\/j.actbio.2025.12.049_bib0045","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41388-022-02587-1","article-title":"Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis","volume":"42","author":"Bhatia","year":"2023","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.actbio.2025.12.049_bib0047","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.3390\/ijms26136042","article-title":"Biodistribution of a mucin 4-selective monoclonal antibody: defining a potential therapeutic agent against pancreatic cancer","volume":"26","author":"Dahal","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.actbio.2025.12.049_bib0048","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/0008-5472.CAN-06-3114","article-title":"Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy","volume":"67","author":"Singh","year":"2007","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.actbio.2025.12.049_bib0049","article-title":"Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect","volume":"14","author":"Ejigah","year":"2022","journal-title":"Polym. (Basel)"},{"issue":"38","key":"10.1016\/j.actbio.2025.12.049_bib0050","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.19452","article-title":"Optimizing molecular weight of octyl chitosan as drug carrier for improving tumor therapeutic efficacy","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget."},{"issue":"2","key":"10.1016\/j.actbio.2025.12.049_bib0051","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1021\/acsptsci.1c00035","article-title":"Lipophilicity determines routes of uptake and clearance, and toxicity of an alpha-particle-emitting peptide receptor radiotherapy","volume":"4","author":"Tafreshi","year":"2021","journal-title":"ACS. Pharmacol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.actbio.2025.12.049_bib0052","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.xphs.2016.01.026","article-title":"Calculated log D is inversely correlated with select camptothecin clearance and efficacy in colon cancer xenografts","volume":"105","author":"Nanavati","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.actbio.2025.12.049_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12Dinhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.actbio.2025.12.049_bib0054","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1535-7163.MCT-18-1206","article-title":"SF2523: dual PI3K\/BRD4 inhibitor blocks tumor immunosuppression and promotes adaptive immune responses in cancer","volume":"18","author":"Joshi","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl 3","key":"10.1016\/j.actbio.2025.12.049_bib0055","article-title":"757 Intratumoral delivery CD40 agonist antibody via novel nanofluidic drug-eluting seed reduced tumor burden of murine pancreatic ductal adenocarcinoma","volume":"8","author":"Liu","year":"2020","journal-title":"J. ImmunOther Cancer"},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0057","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12943-024-02157-x","article-title":"The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS(G12D)-driven non-small cell lung cancer","volume":"23","author":"McDaid","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2025.12.049_bib0058","article-title":"Resistance to the KRASG12Dinhibitor MRTX1133 is associated with increased sensitivity to BET inhibition","author":"Principe","year":"2025","journal-title":"bioRxiv."},{"issue":"19","key":"10.1016\/j.actbio.2025.12.049_bib0059","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1158\/1078-0432.CCR-08-0291","article-title":"Sonic hedgehog promotes desmoplasia in pancreatic cancer","volume":"14","author":"Bailey","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.actbio.2025.12.049_bib0060","doi-asserted-by":"crossref","first-page":"e2996","DOI":"10.1097\/MD.0000000000002996","article-title":"Hedgehog signaling in pancreatic fibrosis and cancer","volume":"95","author":"Bai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.actbio.2025.12.049_bib0061","doi-asserted-by":"crossref","DOI":"10.21037\/apc.2019.05.02","article-title":"Multifunctional role of pancreatic stellate cells in pancreatic cancer","volume":"2","author":"Mekapogu","year":"2019","journal-title":"Ann. Pancreat. Cancer"},{"issue":"7","key":"10.1016\/j.actbio.2025.12.049_bib0063","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1021\/mp500162w","article-title":"PEG\u2013polypeptide block copolymers as pH-responsive endosome-solubilizing drug nanocarriers","volume":"11","author":"Quadir","year":"2014","journal-title":"Mol. Pharm."},{"issue":"29","key":"10.1016\/j.actbio.2025.12.049_bib0064","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1016\/j.biomaterials.2012.06.045","article-title":"Cellular uptake and intracellular trafficking of PEG-b-PLA polymeric micelles","volume":"33","author":"Zhang","year":"2012","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.actbio.2025.12.049_bib0065","first-page":"159","article-title":"pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery","volume":"8","author":"Liu","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"issue":"24","key":"10.1016\/j.actbio.2025.12.049_bib0066","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1016\/S0142-9612(03)00347-8","article-title":"Polyion complex micelles from plasmid DNA and poly (ethylene glycol)\u2013poly (l-lysine) block copolymer as serum-tolerable polyplex system: physicochemical properties of micelles relevant to gene transfection efficiency","volume":"24","author":"Itaka","year":"2003","journal-title":"Biomaterials"},{"issue":"8_Supplement_1","key":"10.1016\/j.actbio.2025.12.049_bib0067","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-5640","article-title":"The KRASG12Dinhibitor MRTX1133 demonstrates significant antitumor activity and enhances nanoparticle-paclitaxel chemotherapy outcomes in pancreatic cancer","volume":"85","author":"Ramos","year":"2025","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.actbio.2025.12.049_bib0068","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-018-0081-3","article-title":"Oncogenic PI3K\/AKT promotes the step-wise evolution of combination BRAF\/MEK inhibitor resistance in melanoma","volume":"7","author":"Irvine","year":"2018","journal-title":"Oncogenesis."},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0069","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11672","article-title":"Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K\/AKT via RAS\u2013p110 crosstalk","volume":"7","author":"Tamaskovic","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2025.12.049_bib0070","doi-asserted-by":"crossref","first-page":"526","DOI":"10.18632\/oncotarget.28441","article-title":"Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma","volume":"14","author":"Pietrobono","year":"2023","journal-title":"Oncotarget."},{"issue":"7","key":"10.1016\/j.actbio.2025.12.049_bib0071","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nm.3613","article-title":"Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition","volume":"20","author":"Tang","year":"2014","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.actbio.2025.12.049_bib0072","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1038\/s41388-021-01783-9","article-title":"Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma","volume":"40","author":"Pietrobono","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.actbio.2025.12.049_bib0073","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00592-020-01582-w","article-title":"YAP mediates the interaction between the Hippo and PI3K\/Akt pathways in mesangial cell proliferation in diabetic nephropathy","volume":"58","author":"Qian","year":"2021","journal-title":"Acta Diabetol."},{"issue":"58","key":"10.1016\/j.actbio.2025.12.049_bib0074","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.21432","article-title":"Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125009560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125009560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:42:49Z","timestamp":1772250169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706125009560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":70,"alternative-id":["S1742706125009560"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.12.049","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Inhibition of KRAS G12D and PI3K\/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.12.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}